期刊文献+

多西他赛联合氟尿嘧啶和亚叶酸钙双周方案治疗晚期胃癌的临床疗效研究 被引量:3

The Effect Research of Biweekly Regimen of Docetaxel Combined with Fluorouracil and Leucovorin Calcium in the Treatment of Advanced Gastric Cancer
暂未订购
导出
摘要 目的研究多西他赛联合氟尿嘧啶和亚叶酸钙双周方案治疗晚期胃癌的临床疗效和不良反应。方法选择2009年6月—2011年8月我科收住的符合条件的晚期胃癌患者40例,治疗方案为多西他赛45mg/m2,静脉滴注1h;亚叶酸钙200mg/m2,静脉滴注2h;氟尿嘧啶375mg/m2,静脉推注10min;氟尿嘧啶2g/m2,静脉灌注46h,以上方案每2周重复1次,每2次为1个疗程,所有患者至少接受2个疗程的治疗。结果 40例均可评价疗效,有效率为62.5%(25/40);无治疗相关死亡,主要不良反应为骨髓抑制、口腔炎及脱发。结论多西他赛+氟尿嘧啶和亚叶酸钙联合化疗双周方案治疗晚期胃癌缓解率较高,不良反应耐受好,是治疗晚期胃癌安全有效的化疗方案。 Objective To research the effect adverse reactions of biweekly regimen of Docetaxel combined with Flu- orouracil and Leueovorin calcium in the treatment of advanced gastric cancer. Methods 40 cases were confirmed by pathological examination in patients with advanced gastric cancer, all the patients had measurable. Treatment options for Docetaxel 45mg/ m2, intravenous drip for 1 hours; Leueovorin calcium 200mg/m2, 2 hour infusion; Fluorouracil 375mg/m2, intravenous injec- tion of 10 minutes; Fluorouracil 2g/m2, intravenous infusion for 46 hours, the above scheme was repeated every 2 weeks, each 2 times for 1 course of treatment, all patients reeeived at least 2 courses. Results 40 patients could be evaluated, the effective rate was 62. 5% (25/40) ; There was no treatment related death, major adverse reactions were bone marrow suppression, sto- matitis and alopeeia. Conclusion The remission rate was high that Doeetaxel + Fluorouracil and Leueovorin calcium combined chemotherapy biweekly regimen in the treatment of advanced gastric cancer, the adverse reaction is tolerant, which is a safe and effective chemotheranv scheme for advanced gastric cancer.
作者 张艳丽 吴军
出处 《实用心脑肺血管病杂志》 2013年第9期81-82,共2页 Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词 多西他赛 醛氢叶酸 氟尿嘧啶 胃肿瘤 治疗结果 Docetaxel Leucovorin Fluorouracil Gastric heoplasms Treatment outcome
  • 相关文献

参考文献4

二级参考文献76

  • 1Munoz N,Franceschi S.Epidemiology of gastric cancer and perspectives for prevention.Salud Publica Mex 1997;39:318-330.
  • 2Kamangar F,Dores GM,Anderson WF.Patterns of cancer incidence,mortality,and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world.J Clin Oncol 2006;24:2137-2150.
  • 3Glimelius B,Ekstrom K,Hoffman K,Graf W,Sjodén PO,Haglund U,Svensson C,Enander LK,Linné T,Sellstrom H,Heuman R.Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.Ann Oncol 1997;8:163-168.
  • 4Webb A,Cunningham D,Scarffe JH,Harper P,Norman A,Joffe JK,Hughes M,Mansi J,Findlay M,Hill A,Oates J,Nicolson M,Hickish T,O'Brien M,Iveson T,Watson M,Underhill C,Wardley A,Meehan M.Randomized trial comparing epirubicin,cisplatin,and fluorouracil versus fluorouracil,doxorubicin,and methotrexate in advanced esophagogastric cancer.J Clin Oncol 1997;15:261-267.
  • 5Wagner AD,Grothe W,Haerting J,Kleber G,Grothey A,Fleig WE.Chemotherapy in advanced gastric cancer:a systematic review and meta-analysis based on aggregate data.J Clin Oncol 2006;24:2903-2909.
  • 6Van Cutsem E,Moiseyenko VM,Tjulandin S,Majlis A,Constenla M,Boni C,Rodrigues A,Fodor M,Chao Y,Voznyi E,Risse ML,Ajani JA.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group.J Clin Oncol 2006;24:4991-4997.
  • 7Cunningham D,Starling N,Rao S,Iveson T,Nicolson M,Coxon F,Middleton G,Daniel F,Oates J,Norman AR.Capecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med 2008;358:36-46.
  • 8Kang Y,Kang WK,Shin DB,Chen J,Xiong J,Wang J,Lichinitser M,Salas MP,Suarez T,Santamaria J.Randomized phase III trial of capecitabine/cisplatin (XP) vs.continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC):efficacy and safety results.Proceedings of the 42nd Annual Meeting of American Society of Clinical Oncology;2006 June 1-5;Chicago,USA.Alexandria:American Society of Clinical Oncology,2006:18s.
  • 9Koizumi W,Narahara H,Hara T,Takagane A,Akiya T,Takagi M,Miyashita K,Nishizaki T,Kobayashi O,Takiyama W,Toh Y,Nagaie T,Takagi S,Yamamura Y,Yanaoka K,Orita H,Takeuchi M.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial):a phase III trial.Lancet Oncol 2008;9:215-221.
  • 10Ajani JA,Rodriguez W,Bodoky G,Moiseyenko V,Lichinitser M,Gorbunova V,Vynnychenko I,Garin A,Lang I,Falcon S.Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS).Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium;2009 January 15-17;San Francisco,USA.

共引文献144

同被引文献31

  • 1蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M]4版.北京:中国协和医科大学出版社,2008:309-311.
  • 2Ott K,Lordick F,Blank S,et al.Gastric cancer:surgery in 2011[J].Langenbeck's Archives of Surgery,2011,396(6):743-758.
  • 3Siewert JR,Stein HJ.Classification of carcinoma of the esophagogastric junction[J].Br J Surg,1998,85(11):1457-1459.
  • 4Stahl M,Walz MK,Stuschke M,et al.Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction[J].J Clin Oncol,2009,27(6):851-856.
  • 5Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors[J].Breast Cancer,2005,12(1),S16-S27.
  • 6Trotti A,Colevas AD,Setser A,et al.CTCAE v3.0,development of a comprehensive grading system for the adverse effects of cancer treatment[J].Semin Radiat Oncol,2003,13(3):176-181.
  • 7Saito H,Osaki T,Murakami D,et al.Effect of age on prognosis in patients with gastric cancer[J].ANZ J Surg,2006,76(6):458461.
  • 8国梁,邓小武,陈明,等.放射和化疗联合应用[M].北京:人民卫生出版社,1999:380-385.
  • 9Macdonald JS.Smalley SR.Benedetti J,et al.Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction[J].N Engl J Med,2001,345(10):725-730.
  • 10Japanese Gastric Cancer Association.Japanese gastric cancer treatment guidelines 2010(ver.3)[J].Gastric Cancer,2011,14(2):113-123.

引证文献3

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部